



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group Art Unit : Not Yet Assigned  
Applicants : Michael J. Yellin et al.  
Serial No. : 09/342,314  
Filed : June 29, 1999  
For : THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM  
(CD40-L) MONOCLONAL ANTIBODY 5C8-1

#4 2/2/00  
T. Gray

January 18, 2000  
New York, New York

Hon. Assistant Commissioner  
for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:  
Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants  
make of record, the following documents, copies of which are  
submitted herewith:

PCT Patent Applications

PCT WO 98/30240, published July 16, 1998.  
PCT WO 98/30241, published July 16, 1998.

OTHER REFERENCES

Press Release from Biogen website ([www.prnewswire.com](http://www.prnewswire.com)), "Biogen Says it Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody", October 21, 1999.

Press Release from Biogen website ([www.prnewswire.com](http://www.prnewswire.com)), "Biogen Says it Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody", November 2, 1999.

Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241).

January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241).

Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).


January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).

For the Examiner's convenience, the above-mentioned documents are listed on the accompanying Form PTO-1449.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the continued examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next communication.


Since this Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a Notice of Allowance under 37 C.F.R. § 1.311, the Commissioner is hereby authorized to charge payment of the \$240.00 fee required pursuant to 37 C.F.R. § 1.17(p) to Deposit Account No. 06-1075\*. The Commissioner is hereby authorized to charge payment of any additional fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075\*.

Respectfully submitted,



Margaret A. Pierri (Reg. No. 30,709)  
Attorney for Applicants  
Stanley D. Liang (Reg. No. 43,753)  
Agent for Applicants  
c/o FISH & NEAVE  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000

I Hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Patent Office on Behalf of  
Client and is not for the use  
of the Patent Office.  
C. F. R. § 1.17(p)  
FEB  
WASHINGTON, D.C. 20231 on

  
Stanley D. Liang

Signature of Person Signing

\* See accompanying Transmittal Letter, filed concurrently herewith in duplicate.